tradingkey.logo

Tempus AI Inc

TEM
View Detailed Chart
54.910USD
+2.470+4.71%
Close 02/06, 16:00ETQuotes delayed by 15 min
9.76BMarket Cap
LossP/E TTM

Tempus AI Inc

54.910
+2.470+4.71%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.71%

5 Days

-8.21%

1 Month

-21.04%

6 Months

-1.12%

Year to Date

-7.01%

1 Year

-15.51%

View Detailed Chart

TradingKey Stock Score of Tempus AI Inc

Currency: USD Updated: 2026-02-06

Key Insights

Tempus AI Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 87.42.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tempus AI Inc's Score

Industry at a Glance

Industry Ranking
65 / 392
Overall Ranking
185 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Tempus AI Inc Highlights

StrengthsRisks
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 116.24% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 693.40M.
Undervalued
The company’s latest PE is -188.90, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 96.30M shares, increasing 4.83% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 42.00K shares of this stock.

Analyst Rating

Based on 17 analysts
Buy
Current Rating
87.419
Target Price
+66.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Tempus AI Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Tempus AI Inc Info

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
Ticker SymbolTEM
CompanyTempus AI Inc
CEOLefkofsky (Eric P)
Websitehttps://investors.tempus.com/
KeyAI